Cranial meningiomas in 411 NF2 patients with proven gene mutations: Clear positional effect of mutations, but absence of female severity effect on age at onset - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Medical Genetics Année : 2011

Cranial meningiomas in 411 NF2 patients with proven gene mutations: Clear positional effect of mutations, but absence of female severity effect on age at onset

Miriam Jane Smith
  • Fonction : Auteur
  • PersonId : 904568
Jenny E Higgs
  • Fonction : Auteur
  • PersonId : 904569
Naomi L Bowers
  • Fonction : Auteur
  • PersonId : 904570
Dorothy Halliday
  • Fonction : Auteur
  • PersonId : 904571
Joan Patterson
  • Fonction : Auteur
  • PersonId : 904572
James Gillespie
  • Fonction : Auteur
  • PersonId : 904573
Susan M Huson
  • Fonction : Auteur
  • PersonId : 904574
Simon R Freeman
  • Fonction : Auteur
  • PersonId : 904575
Simon Lloyd
  • Fonction : Auteur
  • PersonId : 904576
Scott A Rutherford
  • Fonction : Auteur
  • PersonId : 904577
Andrew T King
  • Fonction : Auteur
  • PersonId : 904578
Andrew J Wallace
  • Fonction : Auteur
  • PersonId : 889763
Richard T Ramsden
  • Fonction : Auteur
  • PersonId : 904579

Résumé

Background: Meningiomas have been reported to occur in approximately 50% of neurofibromatosis type 2 (NF2) patients. The NF2 gene is commonly biallelically inactivated in both schwannomas and meningiomas. The spectrum of NF2 mutations consists mainly of truncating (nonsense and frameshift) mutations. A smaller number of patients have missense mutations, which are associated with a milder disease phenotype. Methods: We analysed cumulative incidence and gender effects as well as the genotype-phenotype correlation between the position of the NF2 mutation and the occurrence of meningiomas in a cohort of 411 NF2 patients with proven NF2 mutations. Results and Conclusion: Patients with mutations in exon 14 or 15 were least likely to develop meningiomas (risk to 70 years, 37%) and patients with mutations in exons 1-6 were most likely to develop meningiomas (risk to 70 years, 92%). In our cohort of 411 patients, we found no overall gender bias for occurrence of meningioma in NF2 disease. Cumulative incidence of meningioma was close to 80% by 70 years of age for both males and females, but incidence by age 20 years was higher in males (male, 25%; female, 18%; p=0.023). Conversely we also found an increased risk of meningiomas in women with mosaic NF2 disease.
Fichier principal
Vignette du fichier
PEER_stage2_10.1136%2Fjmg.2010.085241.pdf (105.29 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-00604044 , version 1 (28-06-2011)

Identifiants

Citer

Miriam Jane Smith, Jenny E Higgs, Naomi L Bowers, Dorothy Halliday, Joan Patterson, et al.. Cranial meningiomas in 411 NF2 patients with proven gene mutations: Clear positional effect of mutations, but absence of female severity effect on age at onset. Journal of Medical Genetics, 2011, 48 (4), pp.261. ⟨10.1136/jmg.2010.085241⟩. ⟨hal-00604044⟩

Collections

PEER
58 Consultations
268 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More